This study evaluated whether the 3-minute Step Test, a submaximal measure of cardiorespiratory fitness, can predict cardiometabolic and arterial health in youth with atherosclerosis-promoting cardiometabolic risk factors.

Children and adolescents attended a paediatric preventive cardiology clinic for management of cardiometabolic risk factors. Cardiorespiratory fitness was assessed using a 3-minute Step Test, where an individual steps up/down on a 6-inch step at 24 steps/min for 3 minutes. The percentage of age-predicted maximum heart rate that was attained at the end of the Step Test was recorded as a measure of physiological work (cardiorespiratory fitness). Lifestyle-influenced cardiometabolic risk factors included: body anthropometrics [body mass index z-score, waist-to-height ratio z-score], systolic blood pressure, and serum markers [triglycerides, high-density lipoprotein cholesterol, haemoglobin A1C, alanine aminotransferase, vitamin D]. Arterial function was assessed by measuring pulse wave velocity and was normalised to sex and height-specific z-score.

The sample included 482 patients [age 14.31 ± 2.38 years, 261 (53%) male]. A higher percent predicted peak heart rate strongly correlated with worse lifestyle-influenced cardiometabolic risk factors and with higher pulse wave velocity, suggesting increased arterial stiffness.

Percent predicted peak heart rate from the 3-minute Step Test was associated with cardiometabolic and arterial health. The 3-minute Step Test is an inexpensive, quick, and low-resource-intensive method to estimate cardiorespiratory fitness, cardiometabolic and arterial health in an outpatient clinical setting.

Hyperbolic tapering is increasingly recommended for the gradual reduction of psychiatric drugs to minimise withdrawal symptoms, yet available formulations rarely accommodate the small dose regimens required.

To evaluate whether pharmaceutical manipulation strategies – as proposed in clinical guidelines for hyperbolic tapering – can produce progressively smaller haloperidol doses with adequate accuracy and precision.

Strategies included whole and split tablets, liquid dispensed via dropper or dosing syringe, diluted solutions and tablet suspension, applied under controlled laboratory conditions. Haloperidol was used as a model, following an exponential 10% dose reduction schedule from 5 to 0 mg, generating multiple tapering steps that mirrored real-world scenarios. Drug content was quantified by high-performance liquid chromatography and interpreted according to an adapted pharmacopoeial criterion.

All strategies yielded mean doses within 90–110% of expected values, demonstrating satisfactory accuracy and reproducibility. Variability was higher with tablet splitting, drop-based measurements and tablet suspension (relative standard deviation of 8.0%), whereas the use of whole tablets, dosing syringe and diluted liquid improved precision (relative standard deviation of 3.3%). These findings demonstrate the technical feasibility of achieving progressively smaller doses through standardised manipulation strategies, providing experimental support for hyperbolic tapering in clinical practice.

Although off-label, such approaches currently offer the only practical means for safe dose reduction in the absence of smaller dose formulations, highlighting a regulatory gap between product design and clinical needs. Aligned with clinical guidelines, our findings support manipulation strategies as a practical and reliable component of individualised dose reduction in psychiatric care.

Paediatric mechanical circulatory support with Berlin Heart—EXCOR® Paediatric is predominantly used as a bridge to transplant or recovery, specifically in children up to 30 kg. While survival with ventricular assist devices has improved, insights into morbidity and quality of life remain limited. Safely discharging children, particularly with the new driving unit EXCOR® Active (BH-EA), is now of clinical interest. Multidisciplinary and caregiver perspectives are needed to inform practice.

Through semi-structured interviews with 22 professionals (physicians, nurses, psychologists, engineers, physiotherapists, social workers, child education specialists, chaplains) and three caregivers of hospitalised children on BH-EA, we explored: (1) device safety and daily care; (2) hospital environmental factors; (3) requirements for transitioning home with EXCOR® Active.

Qualitative analysis yielded three main themes; of which two are explored in this publication: alarm management and home-discharge requirements for paediatric BH-EA patients. Participants described frequent low-priority alarms contributing to alarm fatigue. They called for clearer procedures, shared responsibilities, and enhanced caregiver training and identified prerequisites for safe discharge, including a 24/7 emergency hotline, remote monitoring, comprehensive system-wide support, caregiver training, and strong healthcare networks.

The interviews highlight that the BH-EA alarm management is conceptualised for in-hospital care, which leads to reservations concerning reliable home monitoring during medical events, such as blood clot formation. Multidisciplinary efforts are essential to enhance device safety, empower caregivers, and develop effective discharge programmes for children on BH-EA. Furthermore, organ allocation systems should be adjusted to avoid disadvantages in organ waiting times following home discharge.